Fertility Services Market Size, Share, Growth, and Industry Analysis, By Type (Male Infertility, Female Infertility), By Application (Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

FERTILITY SERVICES MARKET OVERVIEW

The global Fertility Services Market size estimated at USD 58.68 billion in 2026 and is projected to reach USD 335.92 billion by 2035, growing at a CAGR of 21.39% from 2026 to 2035.

The Fertility Services Market continues to expand as infertility affects approximately 17% of the global adult population, equivalent to nearly 1 in 6 individuals during their reproductive years. More than 3.0 million assisted reproductive technology (ART) cycles are performed worldwide every year, resulting in over 500,000 births annually. In-vitro fertilization (IVF) accounts for nearly 72% of all advanced fertility treatments, while intrauterine insemination (IUI) represents approximately 21% of fertility procedures. Delayed parenthood has increased significantly, with the average maternal age exceeding 30 years in many developed economies. More than 65% of fertility clinics now utilize digital embryo imaging, while genetic embryo screening is incorporated into nearly 48% of IVF procedures, improving implantation success and treatment precision.

The United States remains one of the largest fertility services markets, supported by more than 540 fertility clinics performing over 413,000 ART cycles annually. Approximately 97,000 infants are born every year through assisted reproductive technologies, representing nearly 2.6% of all births nationwide. Female infertility affects around 11% of women aged 15–49, while male infertility contributes to nearly 40% of diagnosed infertility cases. More than 36 states have active fertility clinics offering IVF, ICSI, embryo freezing, donor programs, and fertility preservation services. Elective egg freezing procedures have increased by over 31% during the past few years due to delayed family planning and improved reproductive awareness.

KEY FINDINGS

LATEST TRENDS

Artificial intelligence has become one of the strongest trends transforming the Fertility Services Market. Nearly 42% of newly established IVF laboratories now integrate AI-supported embryo grading systems that evaluate embryo morphology with improved consistency. Time-lapse embryo monitoring technology has been adopted by approximately 46% of advanced fertility clinics, reducing manual observation while improving embryo selection accuracy. More than 48% of IVF procedures now include preimplantation genetic testing (PGT), enabling clinicians to identify chromosomal abnormalities before embryo transfer. Digital patient management systems have also expanded rapidly, with approximately 64% of fertility centers utilizing cloud-based scheduling, electronic medical records, and laboratory management platforms.

Fertility preservation continues gaining momentum across both medical and elective applications. Egg freezing procedures now represent approximately 19% of all female fertility preservation treatments, while sperm banking accounts for over 34% of preservation services globally. Cancer-related fertility preservation referrals have increased by nearly 27% due to improved oncology survivorship programs. Donor egg utilization contributes almost 18% of IVF cycles in several developed healthcare systems, while frozen embryo transfer procedures exceed 55% of all embryo transfers because of higher clinical flexibility and improved endometrial preparation.

MARKET DYNAMICS

Driver

Rising prevalence of infertility and delayed parenthood.

Infertility continues to affect approximately 17% of adults worldwide, making reproductive healthcare a growing medical priority. Female reproductive disorders including polycystic ovary syndrome affect nearly 10% of women of reproductive age, while endometriosis impacts approximately 190 million women globally. Male infertility contributes to almost 40% of infertility diagnoses, increasing demand for comprehensive fertility evaluations. The average maternal age at first childbirth now exceeds 30 years across many developed economies, reducing natural fertility rates and increasing IVF utilization.

Restraint

High treatment costs and inconsistent reimbursement policies.

Despite increasing awareness, fertility treatment affordability remains a major challenge. Approximately 46% of patients identify treatment expenses as the primary obstacle to initiating IVF therapy. Insurance coverage remains limited in numerous countries, with comprehensive reimbursement available in only a small number of healthcare systems. Nearly 28% of patients discontinue treatment after unsuccessful IVF cycles because of financial limitations. Medication expenses account for approximately 35% of total treatment costs, while laboratory procedures contribute nearly 40%.

Expansion of fertility preservation and personalized reproductive medicine

Opportunity

Fertility preservation services continue creating significant opportunities for specialized providers. Egg freezing demand has increased by approximately 31%, particularly among women delaying pregnancy for professional or personal reasons. Cancer-related fertility preservation referrals have expanded by 27% as oncology care increasingly integrates reproductive counseling before chemotherapy.

Personalized reproductive medicine is becoming standard practice, with genetic embryo testing utilized in nearly 48% of IVF cycles. AI-assisted embryo assessment adoption exceeds 42%, improving embryo selection efficiency.

Variable clinical outcomes and regulatory complexity

Challenge

Although fertility technologies continue advancing, treatment success varies significantly according to patient age and medical history. Women younger than 35 generally experience higher IVF success rates than patients above 40, influencing patient expectations and treatment planning.

Regulatory requirements governing embryo storage, donor gametes, genetic testing, and surrogacy differ across more than 60 national jurisdictions, complicating international fertility service operations. Laboratory accreditation standards continue becoming more stringent, requiring investment in quality assurance systems.

•   
•   
  

  Download Free Sample to learn more about this report

    

FERTILITY SERVICES MARKET SEGMENTATION

By Type

• Male Infertility: Male infertility accounts for approximately 29% of the Fertility Services Market, driven by increasing awareness of male reproductive health and improved diagnostic capabilities. Clinical studies indicate that male factors contribute to nearly 40% of infertility cases, making comprehensive male fertility assessment an essential component of assisted reproduction. Semen analysis remains the primary diagnostic test, while advanced procedures such as sperm DNA fragmentation testing, hormonal profiling, and genetic screening are becoming more common. Intracytoplasmic sperm injection (ICSI) is utilized in over 70% of IVF procedures involving male infertility, significantly improving fertilization outcomes.

• Female Infertility: Female infertility represents nearly 71% of the Fertility Services Market and remains the largest service category due to ovarian disorders, tubal diseases, endometriosis, polycystic ovary syndrome (PCOS), and age-related fertility decline. Women above 35 years increasingly seek fertility evaluation because natural fertility decreases with advancing maternal age. IVF continues to be the preferred treatment option, accounting for more than 62% of assisted reproductive procedures. Frozen embryo transfer exceeds 60% of embryo transfers, improving implantation outcomes while reducing ovarian stimulation risks.

By Application

• Fertility Clinics: Fertility clinics account for approximately 61% of the Fertility Services Market because they provide highly specialized reproductive healthcare supported by dedicated embryology laboratories and multidisciplinary medical teams. More than 460 fertility clinics operate across the United States alone, while thousands of specialized centers serve patients globally. IVF procedures constitute nearly 99% of assisted reproductive treatments offered by these facilities. Single embryo transfer has surpassed 80% in many advanced clinics, reducing multiple pregnancy risks while maintaining favorable pregnancy outcomes.

• Hospitals: Hospitals contribute approximately 23% of the Fertility Services Market by integrating reproductive medicine within comprehensive healthcare systems. Large tertiary hospitals offer fertility evaluation, reproductive surgery, IVF, fertility preservation, and maternal care under one clinical network. Surgical treatment for endometriosis, uterine fibroids, and tubal disorders continues supporting fertility restoration in selected patients. More than 65% of university hospitals now maintain reproductive endocrinology departments capable of performing advanced fertility procedures.

• Surgical Centers: Surgical centers represent approximately 9% of the Fertility Services Market by performing minimally invasive reproductive procedures that improve fertility outcomes before assisted reproduction. Laparoscopic surgery remains the preferred treatment for endometriosis, pelvic adhesions, ovarian cysts, and tubal abnormalities. Hysteroscopic procedures are widely used for uterine septum correction, endometrial polyp removal, and submucosal fibroid management. Same-day discharge exceeds 90% following minimally invasive fertility surgery, improving patient convenience and reducing hospitalization.

• Clinical Research Institutes: Clinical research institutes account for approximately 7% of the Fertility Services Market by advancing reproductive science through clinical trials, laboratory innovation, and translational medicine. More than 1,000 reproductive clinical studies have investigated embryo development, fertility preservation, ovarian stimulation, and reproductive genetics during recent years. AI-assisted embryo assessment, time-lapse embryo imaging, and genomic embryo analysis remain major research priorities. Over 40% of advanced IVF cycles now utilize genetic testing methods developed through collaborative research.

•   
•   
  Download Free Sample to learn more about this report

    

FERTILITY SERVICES MARKET REGIONAL INSIGHTS

• North America

North America leads the Fertility Services Market with an estimated 39% market share, supported by advanced reproductive healthcare infrastructure, favorable technology adoption, and a high concentration of specialized fertility clinics. The region operates more than 700 fertility centers, with the United States contributing over 540 clinics.

More than 413,000 assisted reproductive technology cycles are performed annually in the United States, resulting in approximately 97,000 live births through ART. Female infertility affects nearly 11% of women aged 15–49, while male infertility contributes to approximately 40% of diagnosed infertility cases. The widespread use of advanced technologies strengthens regional leadership.

• Europe

Europe represents approximately 31% of the global Fertility Services Market and remains one of the most mature assisted reproductive technology markets. Countries including Spain, Germany, the United Kingdom, France, Italy, Denmark, Belgium, and the Netherlands collectively perform more than 1.1 million fertility treatment cycles annually.

Several European countries provide partial or complete reimbursement for fertility treatment, improving patient accessibility and encouraging earlier intervention. Approximately 52% of IVF cycles across Europe involve frozen embryo transfer, reflecting growing confidence in cryopreservation technologies. Preimplantation genetic testing is incorporated into nearly 46% of advanced IVF procedures, while donor egg programs account for approximately 17% of treatment cycles.

• Asia-Pacific

Asia-Pacific accounts for approximately 23% of the Fertility Services Market and represents the fastest-expanding regional healthcare ecosystem due to increasing infertility prevalence, delayed marriages, and growing access to specialized reproductive care. Countries including China, Japan, India, South Korea, Australia, Singapore, and Thailand continue expanding fertility treatment capacity through public and private investment. More than 1,000 specialized fertility centers operate throughout the region.

China performs several hundred thousand IVF procedures annually, supported by increasing reproductive healthcare investments and gradual policy adjustments encouraging childbirth. Japan remains one of the world's largest IVF treatment providers, while Australia maintains one of the highest ART utilization rates per capita.

• Middle East & Africa

The Middle East & Africa account for approximately 7% of the Fertility Services Market, with increasing healthcare investment gradually expanding access to assisted reproductive technologies. Countries including the United Arab Emirates, Saudi Arabia, Israel, South Africa, Egypt, and Qatar have established specialized fertility centers equipped with modern embryology laboratories and advanced IVF technologies. More than 250 dedicated fertility clinics operate across the region.

Infertility affects approximately 15% of couples across several Middle Eastern countries, supporting rising demand for reproductive healthcare services. IVF remains the most frequently performed fertility treatment, representing approximately 69% of advanced reproductive procedures. Fertility preservation services have expanded by nearly 24%, while embryo cryopreservation adoption continues increasing among urban fertility centers.

LIST OF TOP FERTILITY SERVICES COMPANIES

• Instituto Bernabeu SL
• The Cooper Companies Inc.
• Merck KGaA
• Monash IVF Group Ltd.
• CRITEX GmbH
• Vitrolife AB
• Esco Micro Pte. Ltd.
• Anecova SA
• INVO Bioscience Inc.
• Virtus Health Ltd.

List Of Top 2 Companies Market Share

• The Cooper Companies Inc. – Holds an estimated 16% share among leading fertility services and reproductive technology providers through its extensive portfolio of fertility solutions, donor products, reproductive genetics support, and global clinical partnerships spanning more than 100 countries.
• Merck KGaA – Accounts for approximately 13% market share within fertility treatment products and reproductive healthcare solutions.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Fertility Services Market continues to accelerate as infertility affects approximately 17% of adults worldwide and more than 3.0 million assisted reproductive technology (ART) cycles are performed each year. Private healthcare investors are increasingly funding fertility clinic expansion, embryology laboratories, cryopreservation facilities, and reproductive genetics centers. Approximately 61% of fertility treatments are conducted in specialized fertility clinics, making this segment the primary target for infrastructure investment.

Digital transformation has become another important investment area. Nearly 64% of fertility centers now operate electronic patient management systems, while approximately 42% have adopted artificial intelligence for embryo grading and selection. Investments in laboratory automation have improved workflow efficiency by reducing manual embryo assessment and increasing operational consistency. More than 48% of IVF procedures now integrate preimplantation genetic testing, creating additional opportunities for molecular diagnostic laboratories and reproductive genetics providers.

NEW PRODUCT DEVELOPMENT

Innovation within the Fertility Services Market is increasingly focused on improving embryo quality assessment, laboratory automation, reproductive genetics, and patient-centered treatment planning. Approximately 46% of advanced fertility laboratories now utilize time-lapse embryo monitoring systems that continuously evaluate embryo development without disturbing incubation conditions. Artificial intelligence-supported embryo grading has reached nearly 42% adoption among technologically advanced fertility centers, improving embryo selection consistency.

Genetic technologies continue advancing rapidly. Nearly 48% of IVF procedures now incorporate preimplantation genetic testing to improve embryo selection before transfer. Non-invasive embryo assessment methods are also under development, allowing embryologists to evaluate embryo viability while minimizing laboratory intervention. More than 55% of embryo transfer procedures now involve frozen embryos supported by advanced vitrification technologies that improve post-thaw survival. New fertility preservation solutions continue expanding beyond traditional medical applications.

FIVE RECENT DEVELOPMENTS (2023-2025)

• September 2023: INVO Bioscience Inc. introduced enhancements to its intravaginal culture fertility technology, improving patient-centered assisted reproductive treatment options. The updated solution focused on increasing accessibility, simplifying IVF procedures, and supporting fertility clinics seeking cost-efficient reproductive treatment alternatives.
• March 2024: Monash IVF Group Ltd. expanded its fertility service network by opening additional reproductive treatment facilities equipped with digital embryology laboratories, advanced cryopreservation systems, and enhanced fertility preservation capabilities. The expansion increased patient capacity while strengthening regional access to specialized reproductive healthcare.
• June 2024: Vitrolife AB launched an advanced embryo culture media solution designed to improve embryo development consistency during IVF procedures. The innovation complements the company's existing time-lapse imaging and genetic testing portfolio while supporting optimized embryology laboratory workflows and improved clinical performance.
• October 2024: Merck KGaA expanded its fertility technology collaboration by introducing enhanced digital training programs and reproductive laboratory support solutions for fertility specialists. The initiative strengthened clinical education across more than 40 countries while improving standardized treatment protocols and reproductive healthcare quality.
• February 2025: The Cooper Companies Inc. introduced an expanded digital fertility management platform integrating laboratory workflow optimization, AI-assisted embryo assessment, and patient communication tools. The platform supports more than 200 clinical performance indicators, improving operational efficiency, treatment planning, and laboratory quality management across fertility centers.

FERTILITY SERVICES MARKET REPORT COVERAGE

The Fertility Services Market report provides comprehensive analysis covering infertility prevalence, assisted reproductive technologies, fertility preservation, reproductive genetics, laboratory innovations, and regional healthcare developments. The report evaluates approximately 17% global infertility prevalence together with more than 3.0 million annual assisted reproductive technology cycles and over 500,000 ART-related births worldwide. It analyzes IVF, ICSI, embryo cryopreservation, sperm banking, egg freezing, donor programs, and preimplantation genetic testing using verified clinical and healthcare statistics.

The report includes detailed segmentation across 2 major service types and 4 application categories, providing market share analysis supported by relevant numerical data. Regional assessment covers North America, Europe, Asia-Pacific, and the Middle East & Africa, highlighting treatment volumes, fertility clinic distribution, technology adoption, regulatory environments, and healthcare infrastructure. Company profiling evaluates leading participants based on reproductive technology portfolios, geographic presence, laboratory capabilities, innovation strategies, and competitive positioning.